{
     "PMID": "28269787",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20180226",
     "LR": "20180226",
     "IS": "1875-8908 (Electronic) 1387-2877 (Linking)",
     "VI": "57",
     "IP": "2",
     "DP": "2017",
     "TI": "Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.",
     "PG": "447-459",
     "LID": "10.3233/JAD-161223 [doi]",
     "AB": "The probable-amnestic (Pr-a) mild cognitive impairment (MCI)-storage subtype is a phenotype with 8.5 times more risk of conversion to dementia, mainly Alzheimer's disease (AD), than the possible non-amnestic (Pss-na) MCI. The aim of this study was to find the optimized cognitive composites (CCs) domain scores most related to neuroimaging biomarkers within Pr-aMCI-storage subtype patients. The Fundacio ACE (ACE) study with 20 Pr-aMCI-storage subtype subjects (MCI) were analyzed. All subjects underwent a neuropsychological assessment, a structural MRI, FDG-PET, and PIB-PET. The adjusted hippocampal volume (aHV) on MRI, the standard uptake value ratio (SUVR) on FDG-PET and PIB-PET SUVR measures were analyzed. The construction of the CCs domain scores, and the aHV on MRI and FDG-PET SUVR measures, were replicated in the parental AB255 study database (n = 133 MCI). Partial correlations adjusted by age, gender, and education were calculated with the associated p-value among every CC domain score and the neuroimaging biomarkers. The results were replicated in the \"MCI due to AD\" with memory storage impairments from ADNI. Delayed Recall CC domain score was significantly correlated with PIB-PET SUVR (beta= -0.61, p = 0.003) in the ACE study and also with aHV on MRI (beta= 0.27, p = 0.01) and FDG-PET SUVR (beta= 0.27, p = 0.01) in the AB255 study. After a median survival time of 20.6 months, 85% from the ACE MCI converted to AD. The replication of our results in the ADNI dataset also confirmed our findings. Delayed Recall is the CC domain score best correlated with neuroimaging biomarkers associated with prodromal AD diagnosis.",
     "FAU": [
          "Espinosa, Ana",
          "Alegret, Montserrat",
          "Pesini, Pedro",
          "Valero, Sergi",
          "Lafuente, Asuncion",
          "Buendia, Mar",
          "San Jose, Itziar",
          "Ibarria, Marta",
          "Tejero, Miguel A",
          "Gimenez, Joan",
          "Ruiz, Susana",
          "Hernandez, Isabel",
          "Pujadas, Francesc",
          "Martinez-Lage, Pablo",
          "Munuera, Josep",
          "Arbizu, Javier",
          "Tarraga, Lluis",
          "Hendrix, Suzanne B",
          "Ruiz, Agustin",
          "Becker, James T",
          "Landau, Susan M",
          "Sotolongo-Grau, Oscar",
          "Sarasa, Manuel",
          "Boada, Merce"
     ],
     "AU": [
          "Espinosa A",
          "Alegret M",
          "Pesini P",
          "Valero S",
          "Lafuente A",
          "Buendia M",
          "San Jose I",
          "Ibarria M",
          "Tejero MA",
          "Gimenez J",
          "Ruiz S",
          "Hernandez I",
          "Pujadas F",
          "Martinez-Lage P",
          "Munuera J",
          "Arbizu J",
          "Tarraga L",
          "Hendrix SB",
          "Ruiz A",
          "Becker JT",
          "Landau SM",
          "Sotolongo-Grau O",
          "Sarasa M",
          "Boada M"
     ],
     "AD": "Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Araclon Biotech S.L., Zaragoza, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Deparment of Psychiatry, Hospital Universitari Vall d'Hebron, CIBERSAM, Universitat Autonoma de Barcelona, Barcelona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Araclon Biotech S.L., Zaragoza, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Clinica Corachan, Barcelona, Spain. Clinica Corachan, Barcelona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Department of Neurology, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. Fundacion CITA, Centro de Investigacion y Terapias Avanzadas, Alzheimer, San Sebastian, Spain. Hospital Universitari Germans Trias i Pujol, Unitat RM Badalona, Institut de diagnostic per la imatge, Badalona, Spain. Clinica Universitaria de Pamplona, Pamplona, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Pentara Corporation, Salt Lake City, UT, USA. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA. Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain. Araclon Biotech S.L., Zaragoza, Spain. Research Center and Memory Clinic, Fundacio ACE, Institut Catala de Neurociencies Aplicades, Alzheimer Barcelona, Spain.",
     "CN": [
          "AB255 Study Group",
          "Alzheimer's Disease Neuroimaging Initiative"
     ],
     "LA": [
          "eng"
     ],
     "GR": [
          "P50 AG005133/AG/NIA NIH HHS/United States",
          "U01 AG024904/AG/NIA NIH HHS/United States"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "Netherlands",
     "TA": "J Alzheimers Dis",
     "JT": "Journal of Alzheimer's disease : JAD",
     "JID": "9814863",
     "RN": [
          "0 (2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole)",
          "0 (Aniline Compounds)",
          "0 (Radiopharmaceuticals)",
          "0 (Thiazoles)",
          "0Z5B2CJX4D (Fluorodeoxyglucose F18)"
     ],
     "SB": "IM",
     "MH": [
          "Aged",
          "Aged, 80 and over",
          "Alzheimer Disease/diagnosis/metabolism/psychology",
          "Aniline Compounds",
          "Brain/*diagnostic imaging/metabolism",
          "Cognitive Dysfunction/*diagnosis/metabolism/*psychology",
          "Female",
          "Fluorodeoxyglucose F18",
          "Humans",
          "*Magnetic Resonance Imaging",
          "Male",
          "Mental Recall",
          "Neuroimaging",
          "*Neuropsychological Tests",
          "Organ Size",
          "*Positron-Emission Tomography",
          "Prodromal Symptoms",
          "Radiopharmaceuticals",
          "Survival Analysis",
          "Thiazoles"
     ],
     "PMC": "PMC5366247",
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "amnestic mild cognitive impairment",
          "amyloid",
          "cognition",
          "hippocampus",
          "magnetic resonance imaging",
          "memory",
          "positron emission tomography"
     ],
     "EDAT": "2017/03/09 06:00",
     "MHDA": "2018/02/27 06:00",
     "CRDT": [
          "2017/03/09 06:00"
     ],
     "PHST": [
          "2017/03/09 06:00 [pubmed]",
          "2018/02/27 06:00 [medline]",
          "2017/03/09 06:00 [entrez]"
     ],
     "AID": [
          "JAD161223 [pii]",
          "10.3233/JAD-161223 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Alzheimers Dis. 2017;57(2):447-459. doi: 10.3233/JAD-161223.",
     "term": "hippocampus"
}